{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:39Z","timestamp":1793823999524,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/Y00468X\/1"],"award-info":[{"award-number":["MR\/Y00468X\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21\/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools. This trial aims to assess whether seasonal mass vaccination with R21 reduces malaria transmission in The Gambia and Burkina Faso, two countries at the extreme of the transmission spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multi-centre open cluster-randomised controlled trial to assess the impact of mass vaccination with R21 on malaria transmission and morbidity. The trial will be implemented in eastern Gambia (low to moderate transmission) and Central Burkina Faso (intense transmission). Thirty medium-sized villages in The Gambia and 24 in Burkina Faso will be randomised (1:1) to either intervention or control arm. All eligible residents in intervention villages will receive R21 vaccinations in three-monthly rounds, from May to July 2024, prior to the malaria transmission season. A booster vaccine dose will be administered the following year, in June 2025. The primary outcome is malaria prevalence at peak transmission (November 2024). Secondary outcomes include safety and tolerability, incidence of clinical malaria, vaccination coverage and community acceptability, cost and cost-effectiveness of the intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first trial on seasonal mass vaccination aiming at reducing malaria transmission. Strengths of the study include its design as an adequately powered cluster-randomised trial and the inclusion of study sites with differing transmission intensity which will also provide safety and efficacy data for different age groups. Key challenges remain vaccine hesitancy and vaccination coverage. If successful, R21 seasonal mass vaccination will be an innovative intervention to accelerate malaria elimination efforts and reach the goal set in the Global Technical Strategy for malaria 2016\u20132030.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinical trials.gov, NCT06578572. Registered on 27 March 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09048-6","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:15:38Z","timestamp":1759166138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Seasonal mass vaccination with R21\/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Edgard D.","family":"Dabira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Magloire","family":"Natama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatou","family":"Jaiteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen Peeters","family":"Grietens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadima Y.","family":"Bocoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Ousmane","family":"Ndiath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuredin","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balla","family":"Gibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V S","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Erhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"9048_CR1","unstructured":"World Health Organization. World malaria report report. 2024. 283 p. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024 Acessed 25 January 2025."},{"key":"9048_CR2","unstructured":"World Health Organization. World Malaria Report: 20 years of global progress and https:\/\/www.who.int\/publications\/i\/item\/9789240015791. Acessed 27 January 2025"},{"issue":"1","key":"9048_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-023-01110-2","volume":"12","author":"ST Wafula","year":"2023","unstructured":"Wafula ST, Habermann T, Franke MA, May J, Puradiredja DI, Lorenz E, et al. What are the pathways between poverty and malaria in sub-Saharan Africa? A systematic review of mediation studies. Infect Dis Poverty. 2023;12(1):1\u201318.","journal-title":"Infect Dis Poverty"},{"issue":"6872","key":"9048_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/415680a","volume":"415","author":"J Sachs","year":"2002","unstructured":"Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680\u20135.","journal-title":"Nature"},{"issue":"52","key":"9048_CR5","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1016\/j.vaccine.2015.09.099","volume":"33","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Churcher TS, Ghani AC. Vaccine approaches to malaria control and elimination: insights from mathematical models. Vaccine. 2015;33(52):7544\u201350.","journal-title":"Vaccine"},{"key":"9048_CR6","unstructured":"WHO. Malaria vaccines (RTS,S and R21) [Internet]. 2024. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/q-a-on-rts-s-malaria-vaccine. Acessed 12 February"},{"issue":"10437","key":"9048_CR7","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","volume":"403","author":"KP Asante","year":"2024","unstructured":"Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, et al. Feasibility, safety, and impact of the RTS,S\/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet. 2024;403(10437):1660\u201370.","journal-title":"Lancet"},{"issue":"10426","key":"9048_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ou\u00e9draogo JB, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403(10426):533\u201344.","journal-title":"Lancet"},{"key":"9048_CR9","doi-asserted-by":"crossref","unstructured":"Datoo MS, Natama HM, Som\u00e9 A, Bellamy D, Traor\u00e9 O, Rouamba T, et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect Dis. 2022;","DOI":"10.1016\/S1473-3099(22)00442-X"},{"issue":"2","key":"9048_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1086\/589287","volume":"47","author":"AM Dondorp","year":"2008","unstructured":"Dondorp AM, Lee SJ, Faiz MA, Mishra S, Price R, Tjitra E, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis. 2008;47(2):151\u20137.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"9048_CR11","doi-asserted-by":"publisher","first-page":"e873","DOI":"10.1016\/S2214-109X(22)00125-5","volume":"10","author":"C Guinovart","year":"2022","unstructured":"Guinovart C, Siga\u00faque B, Bassat Q, Loscertales MP, Nhampossa T, Ac\u00e1cio S, et al. The epidemiology of severe malaria at Manhi\u00e7a District Hospital, Mozambique: a retrospective analysis of 20 years of malaria admissions surveillance data. Lancet Glob Heal. 2022;10(6):e873\u201381.","journal-title":"Lancet Glob Heal"},{"issue":"1","key":"9048_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-022-04294-4","volume":"21","author":"SO Bittaye","year":"2022","unstructured":"Bittaye SO, Jagne A, Jaiteh LE, Nadjm B, Amambua-Ngwa A, Sesay AK, et al. Clinical manifestations and outcomes of severe malaria in adult patients admitted to a tertiary hospital in the Gambia. Malar J. 2022;21(1):1\u20138.","journal-title":"Malar J"},{"key":"9048_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013Jan;346: e7586.","journal-title":"BMJ"},{"issue":"11","key":"9048_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0187059","volume":"12","author":"J Mwesigwa","year":"2017","unstructured":"Mwesigwa J, Achan J, Di Tanna GL, Affara M, Jawara M, Worwui A, et al. Residual malaria transmission dynamics varies across The Gambia despite high coverage of control interventions. PLoS ONE. 2017;12(11):1\u201324.","journal-title":"PLoS ONE"},{"issue":"21","key":"9048_CR15","first-page":"1","volume":"3099","author":"ED Dabira","year":"2021","unstructured":"Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, et al. Mass drug administration of ivermectin and dihydroartemisinin\u2013piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2021;3099(21):1\u201310.","journal-title":"Lancet Infect Dis"},{"key":"9048_CR16","unstructured":"Institut National de la Statistique et de la D\u00e9mographie BF. Enqu\u00eate D\u00e9mographique et de Sant\u00e9 2021. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/dhsprogram.com\/pubs\/pdf\/PR139\/PR139.pdf. Acessed 31 January 2025"},{"issue":"10016","key":"9048_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387(10016):367\u201375.","journal-title":"Lancet"},{"issue":"12","key":"9048_CR18","doi-asserted-by":"publisher","first-page":"e1782","DOI":"10.1016\/S2214-109X(22)00416-8","volume":"10","author":"HA Thompson","year":"2022","unstructured":"Thompson HA, Hogan AB, Walker PGT, Winskill P, Zongo I, Sagara I, et al. Seasonal use case for the RTS,S\/AS01 malaria vaccine: a mathematical modelling study. Lancet Glob Heal. 2022;10(12):e1782\u201392.","journal-title":"Lancet Glob Heal"},{"issue":"9","key":"9048_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2019-030598","volume":"9","author":"KA Collins","year":"2019","unstructured":"Collins KA, Ouedraogo A, Guelbeogo WM, Awandu SS, Stone W, Soulama I, et al. Investigating the impact of enhanced community case management and monthly screening and treatment on the transmissibility of malaria infections in Burkina Faso: Study protocol for a cluster-randomised trial. BMJ Open. 2019;9(9):1\u201311.","journal-title":"BMJ Open"},{"key":"9048_CR20","unstructured":"Hayes RJ. Cluster Randomised Trials, Second Edition. Chapman and Hall\/CRC; 2017."},{"issue":"3","key":"9048_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001788","volume":"12","author":"N Hofmann","year":"2015","unstructured":"Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med. 2015;12(3):1\u201321.","journal-title":"PLoS Med"},{"issue":"March","key":"9048_CR22","first-page":"1","volume":"6","author":"N Venkatraman","year":"2025","unstructured":"Venkatraman N, Silman D, Bellamy D, Stockdale L, Bowyer G, Edwards NJ, et al. R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18\u201345 years: an open-label, partially blinded, phase 1\u20132a controlled human malaria infection study. The Lancet Microbe. 2025;6(March):1\u201311.","journal-title":"The Lancet Microbe"},{"key":"9048_CR23","doi-asserted-by":"crossref","unstructured":"Venkatraman N, Tiono AB, Bowyer G, Bellamy DG, Stockdale LK, Powlson J, et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso\u202f: two phase 1 , first-in-human trials. 2024;1\u201311. The Lancet Microbe. 2024","DOI":"10.1016\/S2666-5247(24)00084-3"},{"issue":"1","key":"9048_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-019-4467-4","volume":"19","author":"F Camponovo","year":"2019","unstructured":"Camponovo F, Ockenhouse CF, Lee C, Penny MA. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. BMC Infect Dis. 2019;19(1):1\u201315.","journal-title":"BMC Infect Dis"},{"key":"9048_CR25","unstructured":"World Health Organization. Global Malaria Programme operational strategy 2024\u20132030. 2024. 01\u201384 p."},{"issue":"5","key":"9048_CR26","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/ije\/dyad064","volume":"52","author":"K Hemming","year":"2023","unstructured":"Hemming K, Taljaard M. Key considerations for designing, conducting and analysing a cluster randomized trial. Int J Epidemiol. 2023;52(5):1648\u201358.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"9048_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/1740774516646578","volume":"13","author":"AJ Cook","year":"2016","unstructured":"Cook AJ, Delong E, Murray DM, Vollmer WM, Heagerty PJ. Statistical lessons learned for designing cluster randomized pragmatic clinical trials from the NIH health care systems collaboratory biostatistics and design core. Clin Trials. 2016;13(5):504\u201312.","journal-title":"Clin Trials"},{"issue":"34","key":"9048_CR28","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1016\/j.vaccine.2015.04.035","volume":"33","author":"M Schuster","year":"2015","unstructured":"Schuster M, Eskola J, Duclos P, Liang X, Chaudhuri M, Dube E, et al. Review of vaccine hesitancy: rationale, remit and methods. Vaccine. 2015;33(34):4157\u201360.","journal-title":"Vaccine"},{"issue":"2","key":"9048_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0148627","volume":"11","author":"S Dierickx","year":"2016","unstructured":"Dierickx S, Gryseels C, Mwesigwa J, O\u2019Neill S, Bannister-Tyrell M, Ronse M, et al. Factors associated with non-participation and non-adherence in directly observed mass drug administration for malaria in the Gambia. PLoS ONE. 2016;11(2):1\u201312.","journal-title":"PLoS ONE"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09048-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09048-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09048-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:15:41Z","timestamp":1759166141000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09048-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9048"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09048-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6292533\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, informed consent documents, and patient information sheets have been reviewed and approved by The Gambia Government\/MRC Joint Ethics Committee, the London School of Hygiene and Tropical Medicine Ethics Committee (ref number: 29834) and the Comit\u00e9 d'Ethique pour la Recherche en Sant\u00e9 (CERS), Burkina Faso (ref number: 2023-10-242).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed the final draft of the manuscript and agreed on the content and format for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"382"}}